Lupus anticoagulant. Implications for obstetric anaesthetists.

Abstract

Circulating lupus anticoagulant occurs in 5-37% of all patients with systemic lupus erythematosus. Its occurrence is not restricted to collagen vascular disease states. Lupus anticoagulant causes a prolongation of certain laboratory coagulation studies yet it is associated in vivo with a history of systemic intravascular thromboses. Placental vessels are also affected. Less than one in six pregnancies complicated by the presence of this auto-antibody is successful. Treatment of afflicted parturients with anti-platelet therapy has increased perinatal survival rates. Derangements in the coagulation profile and concomitant anti-platelet therapy confound the rational use of regional anaesthesia in the management of labour and delivery in these high-risk pregnancies.

• Authors: A M Malinow, W J Rickford, B L Mokriski, D N Saller, W J McGuinn
• Journal: Anaesthesia (Anaesthesia) Vol. 42 Issue 12 Pg. 1291-3 (Dec 1987) ISSN: 0003-2409 [Print] England
• PMID: 3124665 (Publication Type: Case Reports, Journal Article)

Chemical References

• Autoantibodies
• Blood Coagulation Factors
• Lupus Coagulation Inhibitor
• Thromboplastin

Topics

• Adult
• Anesthesia, General
• Anesthesia, Obstetrical
• Autoantibodies (analysis)
• Blood Coagulation Factors (analysis, immunology)
• Female
• Humans
• Infant, Newborn
• Lupus Coagulation Inhibitor
• Lupus Erythematosus, Systemic (blood, therapy)
• Obstetric Labor Complications (blood, therapy)
• Pregnancy
• Thromboplastin (antagonists & inhibitors)